Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155838 | 0.93 | MAPT (0.54) | KMT2AMEN1HCRTR1HCRTR2HTR7 | |
| SCHEMBL5155030 | 0.85 | MEN1 (0.58) | KMT2AMEN1HCRTR1HCRTR2HTR7 | |
| SCHEMBL746921 | 0.84 | HCRTR2 (0.67) | KMT2AMEN1HCRTR1HCRTR2HTR7 | |
| SCHEMBL5156260 | 0.77 | KMT2A (0.57) | KMT2AMEN1HCRTR1HCRTR2MAPT | |
| SCHEMBL743561 | 0.77 | MEN1 (0.56) | KMT2AMEN1HCRTR1HCRTR2HTR7 | |
| SCHEMBL5152363 | 0.77 | KMT2A (0.65) | KMT2AMEN1HTR7MAPTALDH1A1 | |
| SCHEMBL5156704 | 0.76 | SMN1; SMN2 (0.54) | KMT2AMEN1HTR7SMN1; SMN2MAPT | |
| SCHEMBL745866 | 0.75 | HCRTR2 (0.64) | KMT2AMEN1HCRTR1HCRTR2HTR7 | |
| SCHEMBL746031 | 0.75 | HCRTR2 (0.67) | KMT2AMEN1HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL744589 | 0.75 | HCRTR2 (0.67) | KMT2AMEN1HCRTR1HCRTR2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | KMT2A 4084/4885MEN1 3532/4885HCRTR1 1608/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | KMT2A 3401/4885MEN1 3820/4885HCRTR1 2195/4885 |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | KMT2A 3401/4885MEN1 3820/4885HCRTR1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.